Moleculin Biotech Inc (MBRX.OQ)
23 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Moleculin Biotech Resale By Selling Shareholders Of Up To 2.1 Mln Shares Of Co's Common Stock Issuable Upon Exercise Of Outstanding Warrants
- BRIEF-Moleculin Announces Patients Treated In FDA Approved Phase I/Ii Annamycin Clinical Trial
- BRIEF-Moleculin Biotech Reports Financial Results For The Year Ended Dec 31, 2017
- BRIEF-Moleculin Enters Agreement With Seidman Cancer Center To Conduct Leukemia Clinical Trials
- BRIEF-Moleculin Announces Pricing Of $9 Million Registered Direct Offering